Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10657483 | 0.87 | KDM4E (0.44) | TSHRKDM4EHPGDPDCD1CD274 | |
| SCHEMBL27409421 | 0.82 | KMT2A (0.43) | KDM4EHPGDCTDSP1SMN1; SMN2CHRNB2 | |
| SCHEMBL3507290 | 0.81 | LMNA (0.58) | TSHRKDM4EPDCD1CD274SMN1; SMN2 | |
| SCHEMBL29025475 | 0.79 | ALDH1A1 (0.54) | TSHRPDCD1CD274SMN1; SMN2GAA | |
| SCHEMBL829848 | 0.79 | TSHR (0.44) | TSHRPDCD1CD274SMN1; SMN2GAA | |
| SCHEMBL11298089 | 0.78 | TSHR (0.43) | TSHRPDCD1CD274SMN1; SMN2GAA | |
| SCHEMBL874211 | 0.78 | HPGD (0.53) | TSHRKDM4EHPGDCTDSP1SMN1; SMN2 | |
| SCHEMBL28578519 | 0.77 | TSHR (0.42) | TSHRPDCD1CD274SMN1; SMN2GAA | |
| SCHEMBL28138502 | 0.77 | TSHR (0.59) | TSHRKDM4EHPGDSMN1; SMN2HTT | |
| SCHEMBL2532016 | 0.77 | TSHR (0.42) | TSHRPDCD1CD274SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4727818-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| CN-1206921-C | Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type | NOVO JYMEZ AS (DK) | 2005-06-22 | — | — | CN | claimed |
| EP-1128730-B1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES AS (DK) | 2003-05-02 | — | — | EP | claimed |
| JP-2002529380-A | — | — | 2002-09-10 | — | — | JP | claimed |
| US-20020094331-A1 | ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2002-07-18 | — | — | US | claimed |
| CN-1325270-A | Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type | NOVO JYMEZ AS (DK) | 2001-12-05 | — | — | CN | claimed |
| EP-1128730-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | Novozymes A/S (DK) | 2001-09-05 | — | — | EP | claimed |
| WO-2000027204-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2000-05-18 | — | — | WO | claimed |
| WO-2025242789-A1 | METHOD FOR PRODUCING REINFORCED TEXTILE FIBER COMPOSITIONS | LIGAMORE APS (DK) | 2025-11-27 | — | — | WO | disclosed |
| EP-3444337-B1 | METHOD OF CLEANING | PROCTER & GAMBLE (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3444336-B1 | CLEANING AGENT | PROCTER & GAMBLE (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210147765-A9 | CLEANING KIT | THE PROCTER AND GAMBLE COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210071117-A9 | CLEANING AGENT | THE PROCTER AND GAMBLE COMPANY | 2021-03-11 | — | — | US | disclosed |
| CN-110892065-A | Cleaning method | 宝洁公司 | 2020-03-17 | — | — | CN | disclosed |
| US-20020094331-A1 | ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2002-07-18 | — | — | US | disclosed |
| WO-2002047483-A1 | USE OF HALOPEROXIDASE, PEROXIDE AND CARBOXYLIC ACID | NOVOZYMES A/S (DK) | 2002-06-20 | — | — | WO | disclosed |
| CN-1325270-A | Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type | NOVO JYMEZ AS (DK) | 2001-12-05 | — | — | CN | disclosed |
| EP-1128730-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | Novozymes A/S (DK) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001048304-A1 | PROCESS FOR REMOVAL OF EXCESS DISPERSE DYE FROM PRINTED OR DYED TEXTILE MATERIAL | NOVOZYMES A/S (DK) | 2001-07-05 | — | — | WO | disclosed |
| WO-2000027204-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094331-A1 | ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE | LPO, MPO, LCT | TSHR 4011/4885KDM4E 2516/4885HPGD 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.